HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study.

AbstractBACKGROUND:
Recent studies have established the pivotal role of irritants and allergens in development of chronic paronychia and the significant improvement with corticosteroid therapy.
OBJECTIVES:
The objective of this randomized, unblinded, comparative study was to compare the efficacy of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia.
METHODS:
Forty-five patients with chronic paronychia were randomized 1:1:1 to apply twice daily either betamethasone 17-valerate 0.1% or tacrolimus 0.1% ointment or emollient. Protective measures were counselled to all patients. Treatment duration was 3 weeks and patients were followed for an additional 6 weeks.
RESULTS:
Eight patients in the betamethasone group were considered as cured, two as improved and four as nonresponders at the end of the treatment period. Thirteen patients in the tacrolimus group were considered as cured and one as improved at the end of the treatment period. Nine patients in the emollient group were considered as stable and six failed to respond. Both betamethasone and tacrolimus groups presented statistically significantly greater cure or improvement rates when compared with the emollient group (P<0.001).
CONCLUSIONS:
Tacrolimus ointment appears to be a more efficacious agent than betamethasone 17-valerate or placebo for the treatment of chronic paronychia.
AuthorsD Rigopoulos, S Gregoriou, E Belyayeva, G Larios, G Kontochristopoulos, A Katsambas
JournalThe British journal of dermatology (Br J Dermatol) Vol. 160 Issue 4 Pg. 858-60 (Apr 2009) ISSN: 1365-2133 [Electronic] England
PMID19120329 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Immunosuppressive Agents
  • Ointments
  • Betamethasone Valerate
  • Tacrolimus
Topics
  • Betamethasone Valerate (adverse effects, therapeutic use)
  • Candidiasis (drug therapy)
  • Chronic Disease
  • Female
  • Humans
  • Immunosuppressive Agents (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Ointments
  • Paronychia (drug therapy)
  • Tacrolimus (adverse effects, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: